• US: +1-408-610-2300
  • Toll Free: +1-866-831-4085
  • Login / Register
  • Home
  • » Generic Drugs
  • » Anti-Retroviral Drugs Market Size & Share, 2018 | Industry Report
Anti-Retroviral Drugs Market Size & Share, 2018 | Industry Report

Anti-Retroviral Drugs Industry 2018 Market Research Report

Report ID: MN17616375  |  Published: November 2017  |  No of Pages: 112
Format: Electronic (PDF)  |  Industry: Generic Drugs  |  Publisher: QY Research

The global Anti-Retroviral Drugs Market is likely to display a momentous growth in the near future owing to augmentation in the applications and expansion of the scope across various sectors. Anti-Retroviral Drugs are the drugs or medications that can treat and prove useful in curing HIV. It is said that these drugs do not actually destroy or alleviate the virus but if the medications are taken in combination, they can avert the development of the virus. Further with time, the growth of the virus gets hindered and HIV disease gets gradually treated. Anti-Retroviral drugs can be abbreviated as ARV. Anti-Retroviral Drugs Market is attaining huge recognition across various sectors owing to burgeoning demands and prerequisites.

It is significant that the Anti-Retroviral Drugs Market is growing at a robust rate. The key factors that are influencing the overall market growth positively may entail rise in the demands, rise in the healthcare expenditure by the government authorities, widespread usage, increase in the prerequisites for effective drugs, rise in the occurrences of diseases like HIV and hepatitis, burgeoning applications, and mounting investments in the research and development processes of antivirals. Additionally, the manufacturers are also siding with various strategies such as partnerships, acquisitions, and joint ventures that is ultimately contributing in the inorganic growth of the market. On account of all the above factors, it is estimated that the Anti-Retroviral Drugs market will register a healthy CAGR in the upcoming period.

The factors that are impeding the overall growth of the Anti-Retroviral Drugs market may entail soaring costs of research & development activities and therapies and mounting generic products in the market. Anti-Retroviral Drugs Industry can be split up by product type, application, and geography. The market is segmented by product type as Protease Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Nucleoside Analogs and Nucleoside Reverse Transcriptase Inhibitors, Integrase Inhibitors, and others.

Anti-Retroviral Drugs Market is segregated by application as HIV/AIDS, Hepatitis, Influenza, Herpes, and others. Anti-Retroviral Drugs Industry is divided by geography as North America, Europe, China, Japan, Southeast Asia, and India. Geographically, North America is at present leading the market and it is estimated that the market will experience a higher CGAR in the upcoming years, the reason being augmented awareness among the consumers, rising applications, augmentation in the demands, developing nations, rise in the occurrences of diseases, and growing patient population.

On the contrary, Asia Pacific and European regions are also exhibiting a robust growth in the market due to emergence of huge market growth opportunities, rising significance of the drugs, and developing nations. The key players operating in the robust development of the Anti-Retroviral Drugs Market are identified as Abbott, AstraZeneca, Bristol-Myers-Squibb, Cardiocom, Biotelemetry, GlaxoSmithKline, Roche, Gilead, Cardiac Science Corp., GE Healthcare, and Cardionet.

Market Segment:

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Anti-Retroviral Drugs in these regions, from 2013 to 2025 (forecast), covering
• North America
• Europe
• China
• Japan
• Southeast Asia
• India

Global Anti-Retroviral Drugs market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including
• Cardionet
• GE Healthcare
• Abbott
• AstraZeneca
• Bristol-Myers-Squibb
• Gilead
• Cardiac Science Corp.
• Cardiocom
• Biotelemetry
• GlaxoSmithKline
• Roche

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
• Protease Inhibitors
• Non-Nucleoside Reverse Transcriptase Inhibitors
• Integrase Inhibitors
• Nucleoside Analogs and Nucleoside Reverse Transcriptase Inhibitors

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including
• Hepatitis
• Herpes
• Influenza
• Others

What questions do you have? Get quick response from our industry experts. Request More information
Key questions answered in the report include
key questions
We also offers customization on reports based on specific client requirement.
Request for Customization

Choose License Type

Research Assistance

Ryan Manuel
Ryan Manuel

Research Support Specialist, USA

  1. Phone: +1-408-610-2300
  2. Toll Free: +1-866-831-4085
  3. Email: [email protected]
  • World's largest premium report database
  • Transparent pre & post sale customer engagement model
  • Unparalleled flexibility in terms of rendering services
  • Safe & secure web experience
  • 24*5 Research support service
  • 100% Secure Payments
  • Our Promise
  • 100% Service Assurance
  • Market Monitoring
  • Service Flexibility
  • 24X5 Care available